-
In the past month (July 10-August 10), a large number of pharmaceutical companies in Shanghai and Shenzhen have undergone personnel changes
Time of Update: 2022-08-20
Shuyu civilian: Director resigns Shuyu civilian: Director resigns On August 8, Shuyu Mining announced that the company's board of directors recently received a written resignation application submitted by the company's director, Mr. Li Yubiao, who applied to resign as a non-independent director of the company's third board of directors due to personal reasons, and will no longer hold any positions in the company after resignation.
-
Announcement of the State Food and Drug Administration on Matters Concerning the Filing of Class I Medical Devices
Time of Update: 2022-08-20
For the filed medical devices, the filing department shall provide the filing number with the filing number (see Annex 3 for the notification of filing number), and publish the "Class I Medical Device Filing Information Form" or "Class I In Vitro Diagnostic Reagent Filing Information" according to the prescribed time.
-
In August, these pharmaceutical companies increased their holdings, involving Yahuilong, Xinbang Pharmaceutical, Haier Bio, etc.
Time of Update: 2022-08-20
Since August, a large number of pharmaceutical companies have issued announcements of increasing their shareholdings, involving Yahuilong, Xinbang Pharmaceutical, Haier Bio, Kangtai Bio and other phar
-
The market of 100 billion traditional Chinese medicine formula granules ushered in a new round of expansion, and intelligent manufacturing will help pharmaceutical companies activate the "development password"
Time of Update: 2022-08-20
Traditional Chinese Medicine Industry (Photo Source: Pharmaceutical Network) The market of 100 billion traditional Chinese medicine formula granules ushered in a new round of expansion Chinese herbal formula granules are granules prepared by extracting and concentrating single-flavored Chinese herbal medicine pieces according to traditional standards, and are used for clinical formulation of Chinese medicine.
-
The sales of blockbuster drugs are strong, and the performance of a large number of multinational pharmaceutical companies has increased steadily in the first half of the year
Time of Update: 2022-08-20
593 billion, a year-on-year increase of 28% (excluding the sales of the new crown oral drug LAGEVRIO, which increased by 18% year-on-year); the revenue in the first half of 2022 was US$30.
-
Looking forward to the future, Harbin Pharmaceutical's summer media tea party was successfully held
Time of Update: 2022-08-20
During the conference, the organizers released lists such as the "Top 100 List of China's Pharmaceutical Industry", "2022 List of China's Pharmaceutical Brands", and "Top 100 List of China's Chain Pharmacy Direct Sales" .
-
Shanghai and Yunnan join hands to promote the county-level medical community to share high-quality medical resources for children in Yunnan
Time of Update: 2022-08-20
Under the auspices of Professor Xu Hong, Secretary of the Party Committee of the Pediatric Hospital Affiliated to Fudan University, the Outpatient and Emergency Management Office convened multidisciplinary experts from the Department of Infectious Diseases, Department of Hematology, Department of Rheumatology, and Department of Radiology, Qiao Zhongwei, to conduct remote consultation on Xiaojie's condition .
-
Since August, a large number of biopharmaceutical companies have announced the completion of billion-dollar financing
Time of Update: 2022-08-20
In recent years, global funds are rapidly pouring into the biopharmaceutical industry, driving the sharp rise in the stock prices of pharmaceutical companies, and also driving the continued active investment and financing activities in the BioTCH field .
-
Decision of the State Council on Cancelling and Adjusting a Batch of Fines
Time of Update: 2022-08-20
The people's governments of all provinces, autonomous regions and municipalities directly under the Central Government, all ministries and commissions of the State Council, and all institutions direc
-
Cross-province direct settlement of outpatient chronic and special disease-related treatment fees in Shenyang has been opened
Time of Update: 2022-08-20
health health disease disease high blood pressure high blood pressure It is reported that in the past three years, the state has carried out three consecutive pilot projects in the direct settlement of medical treatment in different places, and Shenyang has become a pilot city .
-
What is the future of medicine market?
Time of Update: 2022-08-20
1. In the future, the pressure of medical insurance will become the norm, and look for a medical insurance immunization track On the one hand, you can focus on self-consumption varieties such as traditional Chinese medicine consumer goods, self-funded biological drugs, as well as relatively high-prosperous tracks such as medical beauty and ophthalmic equipment .
-
Pfizer's third-generation ALK inhibitor Borina(R) successfully held the launch meeting
Time of Update: 2022-08-20
ALK patient education support project launched simultaneously Guangzhou, Aug. 13, 2022 /PRNewswire/ -- Today, Pfizer's innovative lung cancer drug, the world's first third-generation ALK inhibitor Lorbrena® (Lorbrena®, generic name: Lorlatinib Tablets) The China listing meeting was successfully held, and the "online + offline" linkage of 18 cities opened a new pattern of diagnosis and treatment of ALK-positive non-small cell lung cancer (NSCLC) in China .
-
The Shortage Drug List is here!
Time of Update: 2022-08-20
The four departments jointly issued a document requesting to strengthen the monitoring of the production and reserve of drugs in shortage and selected drugs selected by the state . Among them, there
-
The results of 10 popular tests such as Biogen, Merck, Gilead, etc. will be announced!
Time of Update: 2022-08-20
KarXT (Small Molecule Drugs) Company: Karuna Therapeutics Disease : Schizophrenia Test Name: Emergent-2 Brain drug developer Karuna Therapeutics has already had positive results in schizophrenia research, with a study of about 180 participants showing that people taking the drug Karuna (codenamed KarXT) had significantly less symptoms than those taking a placebo .
-
Cash dividends, product reviews, senior executives leaving... The announcement of listed pharmaceutical companies on August 12 is interesting
Time of Update: 2022-08-20
Dirui Medical's 2022 semi-annual report shows that the company achieved operating income of 515 million yuan in the first half of the year, an increase of 23.
-
The research and development of new Chinese medicines is still accelerating, and another class 1 new drug is applied for clinical trials
Time of Update: 2022-08-20
The clinical application of Tongjiang Granules is the company's second class 1 new drug in the Chinese patent medicine stomach medicine market, which is mainly used for the treatment of gastroesophageal reflux disease .
-
MNC's first half report card: Pfizer, Johnson & Johnson, Roche revenue TOP3!
Time of Update: 2022-08-20
6 billion, an increase of 19% year-on-year; the rare disease business grew rapidly, with total revenue reaching US$3.
6 billion, an increase of 19% year-on-year; the rare disease business grew rapidly, with total revenue reaching US$3.
-
Is financing in the domestic medical and health sector still "hot"?
Time of Update: 2022-08-20
In recent years, the rapid development of stem cell therapy in China, and continuous breakthroughs under the continuous advancement of technology, has accelerated the pace of clinical application in many fields such as systemic lupus erythematosus, rheumatoid arthritis, psoriasis, cardiovascular and cerebrovascular diseases, and has broad market prospects.
-
The highest drop is 96.67%!
Time of Update: 2022-08-20
62%; duloxetine hydrochloride enteric-coated capsules (30mg calculated by C18H19NOS) decreased from 171 yuan / bottle dropped to 21.
62%; duloxetine hydrochloride enteric-coated capsules (30mg calculated by C18H19NOS) decreased from 171 yuan / bottle dropped to 21.
-
Pharmaceutical companies are actively exploring the children's drug market, and some companies have raised nearly 297 million yuan
Time of Update: 2022-08-20
For example, Kangzhi Pharmaceutical recently announced that the company plans to raise no more than 297 million yuan, and the net amount of funds raised after deducting issuance expenses is planned to be used for children's drug research and development projects .
